BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

...across the company and are expected to reduce annual operating expenses by over $125M. Its DN24-02...
BioCentury | Nov 18, 2013
Company News

Dendreon cancer news

...said it will continue to invest in manufacturing automation and ongoing clinical development programs. Dendreon's DN24-02...
BioCentury | Jun 17, 2013
Clinical News

DN24-02: Preliminary Phase II data

...urothelial carcinoma in the open-label, U.S. Phase II NeuACT trial showed that 3 infusions of DN24-02...
...chills, fatigue, nausea, headache, vomiting and arthralgia reported as the most common adverse events. Additionally, DN24-02...
...neoadjuvant chemotherapy and in patients who did not. Dendreon also said that product potency of DN24-02...
BioCentury | Oct 24, 2011
Clinical News

DN24-02: Phase II started

...Dendreon began the open-label, U.S. Phase II Neu-ACT trial to compare DN24-02 vs. the standard of...
...invasive urothelial carcinoma, including bladder cancer, following surgical resection. Dendreon Corp. (NASDAQ:DNDN), Seattle, Wash. Product: DN24-02...
BioCentury | Jul 29, 2010
Cover Story

Triglyceride trouble from tumors

...second cancer vaccine, Neuvenge lapuleucel-T , in Phase I testing for breast and ovarian cancers. Neuvenge...
BioCentury | May 3, 2010
Product Development

Building on Provenge

...broader potential beyond prostate cancer. The company's next most advanced program is Neuvenge lapuleucel-T ( APC8024...
BioCentury | Apr 20, 2009
Product Development

Provenge's IMPACT

...of other cancer settings using various antigens. The most advanced of these is lapuleucel-T ( APC8024...
BioCentury | Aug 27, 2007
Clinical News

Neuvenge lapuleucel-T: Additional Phase I data

...D2000-1 (see BioCentury, Dec. 20, 2004). Dendreon Corp. (DNDN), Seattle, Wash. Product: Neuvenge lapuleucel-T ( APC8024...
BioCentury | May 29, 2006
Product Development

Cancer vaccines in development

...105AD7 Anti-idiotype antibody vaccine that mimics the CD55 antigen Colorectal cancer Ph I/II Dendreon Neuvenge (lapuleucel-T...
BioCentury | Dec 20, 2004
Clinical News

APC8024: Interim Phase I data

...in 21 evaluable patients with advanced metastatic HER-2/neu-positive breast cancer showed that 8 weeks of APC8024...
...presented at the Breast Cancer meeting in San Antonio. Dendreon Corp. (DNDN), Seattle, Wash. Product: APC8024...
Items per page:
1 - 10 of 22